Barclays PLC Adma Biologics, Inc. Call Options Transaction History
Barclays PLC
- $377 Billion
- Q3 2024
Call Options
1 transactions
Others Institutions Holding ADMA
# of Institutions
326Shares Held
190MCall Options Held
917KPut Options Held
91.6K-
Black Rock Inc. New York, NY18.6MShares$315 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.1MShares$306 Million0.01% of portfolio
-
State Street Corp Boston, MA13MShares$219 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA12.6MShares$213 Million0.05% of portfolio
-
Morgan Stanley New York, NY8.6MShares$145 Million0.01% of portfolio
About ADMA BIOLOGICS, INC.
- Ticker ADMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 196,356,992
- Market Cap $3.31B
- Description
- ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...